Oruka Therapeutics Inc (ORKA)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | PHARMACEUTICALS |
| SIC: | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| CEO: | Lawrence Klein |
| Employees: | |
| Web site: | ir.orukatx.com |
|
855 OAK GROVE AVE., SUITE 100, MENLO PARK, CA, 94025
650-606-7910
| |
-
Formally known as:
- Hyseq Inc
- Nuvelo Inc
| Date | Ratio |
|---|---|
| 2004-02-23 | 1:3 |
| 2013-03-05 | 1:6 |
| 2015-09-04 | 1:7 |
| 2019-04-04 | 1:18 |
| 2024-09-03 | 1:12 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Our mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice per year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases.
Please log in first to see chart